Chronic kidney disease-mineral and bone disorder (CKD-MBD) is a complex disorder of bone and mineral metabolism that results in an excess risk of fractures, cardiovascular events and mortality. The management of the bone disorder aspect of CKD-MBD may require bone biopsy to determine appropriate treatment strategies. However, it is unclear when biopsy may be necessary and whether or not state-of-the art imaging and serologic testing can supplant the bone biopsy as a tool to assist with management decisions.
INTRODUCTION
Renal osteodystrophy (ROD) is a bone disorder that occurs in chronic kidney disease (CKD) patients and is associated with increased fracture risk. Tetracycline double-labeled transiliac crest bone biopsy with histomorphometry is the gold standard for the diagnosis and classification of ROD. However, bone biopsy is not always practical for all patients. Thus, there is great interest in developing noninvasive approaches that can be used in the clinic to assess ROD in CKD populations. Here we review noninvasive methods and their utility in assessing ROD.
CHRONIC KIDNEY DISEASE-MINERAL AND BONE DISORDER
ROD is a complex disorder of bone due to the individual and combined actions of metabolic and hormonal abnormalities that occur with CKD: hyperphosphatemia, hypocalcemia, hyperparathyroidism (HPT), deficiency of 25(OH)D and decreased renal synthesis of 1,25(OH) 2 D, chronic metabolic acidosis, and premature hypogonadism. These abnormalities impair bone remodeling and mineralization, and result in cortical and trabecular defects. The term CKD-mineral and bone disorders (CKD-MBDs) has been implemented by the Kidney Disease Improving Global Outcomes (KDIGO) working group to refer more broadly to the systemic disorder of mineral and bone metabolism due to CKD. It is characterized by either one or a combination of the following features: abnormalities of calcium, phosphorous, parathyroid hormone (PTH), or vitamin D metabolism; abnormalities of bone
BONE STRENGTH
Bone strength is dependent on both bone density and quality. Bone density is a measure of bone mass or quantity and is measured by dual-energy X-ray absorptiometry (DXA). Bone quality describes bone material properties and includes bone turnover, microarchitecture and mineralization, accumulation of microdamage, and collagen properties. The gold standard for assessing bone strength is tetracycline double-labeled transiliac crest bone biopsy with histomorphometry. Analyses performed on bone biopsy samples measure the volume and microarchitecture of cancellous and cortical compartments, the accumulation of microdamage, mineralization, and remodeling. In CKD, these abnormalities may include defects in bone volume and microarchitecture (cortical porosity, thinning and trabecularization, and trabecular thinning and dropout), in mineralization (osteomalacia), and in remodeling (adynamic bone disease, osteitis fibrosa cystic, or mixed osteodystrophy). Unfortunately, the routine use of bone biopsy to evaluate ROD is not always practical. Bone biopsy is invasive, expensive, not widely available, and physicians performing this procedure require specialized training [1] [2] [3] . Furthermore, once obtained, the biopsy only provides information about the type of bone disorder at one site (the anterior iliac crest) and at one point in time. Thus, noninvasive approaches that can be used in the clinic to diagnose bone disease and monitor treatment responses would be helpful.
CONTEMPORARY FRACTURE EPIDEMIOLOGY IN CHRONIC KIDNEY DISEASE
Fracture is an important clinical outcome in ROD, and its prevention has motivated us to devise disease assessment strategies. In CKD, fractures are common [4] [5] [6] [7] [8] [9] , increase in proportion to CKD severity [6,10 & ,11] , and are associated with excess morbidity, mortality and health economic costs [12,13,14 && [18] used Medicare data from 1993 to 2010 to investigate hip fracture incidence in ESRD patients compared with the general population and reported similar results. Potential explanations for decreasing hip fracture incidence rates in ESRD patients may include patient-specific characteristics and changes in CKD-MBD management. Kidney transplant recipients are also susceptible to fracture [5, 8, 19, 20] . Over the first 3 years of transplantation, hip fracture risk is 34% higher than patients on dialysis [5] , and hip and spine fracture risk are more than four-fold and 23-fold higher, respectively [20] , than the general population, and about one-quarter of recipients will fracture within the first 5 years of transplantation [19] .
These recent epidemiologic data confirm that fractures remain a serious and alarming CKD-MBD
KEY POINTS
Renal osteodystrophy is a complex bone disorder that is associated with a high risk of fractures, morbidity and mortality.
New data from prospective fracture studies in CKD populations indicate that low areal BMD measured by DXA predicts future fractures.
Advances in imaging methods now provide the ability to noninvasively assess microarchitectural aspects of bone quality that correlate with decreases in bone strength.
Noninvasive assessment of bone turnover and mineralization is still suboptimal.
Future research needs to focus on developing noninvasive methods to measure turnover and mineralization and to study whether combining measures of bone structure by imaging with measures of turnover by serum biochemistries quantifies disease severity, predicts fracture and informs treatment decisions.
complication, in particular, as they are associated with high morbidity, mortality, and cost. In one study, one-third to almost half of hemodialysis patients admitted with a fracture were discharged to a skilled nursing facility after the incident hospitalization. During the year after discharge, patients had an adjusted mean of 3.8-5.2 additional hospitalizations, comprising on average an extra 33-52 inpatient days compared with patients without frac-
]. Moreover, after hip fracture, mortality risk was reported to increase by 16 [15 & ] to 60% [13] , and was associated with high economic costs [21] .
MECHANISMS OF DECREASED BONE STRENGTH IN CHRONIC KIDNEY DISEASE FROM BONE HISTOLOGY
Recent bone biopsy studies have increased our understanding of how ROD affects bone strength, and suggest that a noninvasive assessment of bone disease must measure the underlying microstructural and dynamic defects in bone quality that drive decreases in bone strength [22,23 & ]. Malluche et al. [22] reported findings from 630 biopsies obtained from patients in the United Stated and Europe. Their mean age was 55 AE 1 years, 48% were women, 14% were blacks, 5% were on peritoneal dialysis, and mean dialysis history was 51 AE 1.8 months. There were notable race differences in bone quality. Low turnover predominated in whites (62%) and normal turnover predominated in blacks (68%). Mineralization defects were rare (3% of patients). Trabecular bone volume was low in one-third of whites and high in two-thirds of blacks; for both races, low trabecular volume was associated with thinned rather than lost trabeculae. The majority of blacks had normal cortical thickness but high porosity, whereas there was approximately the same number of whites with low or normal cortical thickness, and normal or high cortical porosity. Abnormal microarchitecture was associated with abnormal turnover. High turnover was associated with a greater severity of cortical porosity, and low turnover was associated with lower trabecular volume and thinner cortices. Malluche et al. [23 & ] also reported on the relationship between bone quality and strength in 35 CKD-5D (hemodialysis) patients. Low turnover was associated with lower trabecular volume than either normal or high turnover. High turnover was associated with lower relative mineral content. Similar to their larger publication of 630 patients, low trabecular volume was associated with thinned trabeculae. Regarding bone mechanical competence (i.e., strength), bone with high turnover had lower stiffness and failure load than bone with normal or low turnover.
IMAGING BONE DISEASE IN CHRONIC KIDNEY DISEASE
DXA, quantitative computed tomography (QCT), and high resolution peripheral computed tomography (HR-pQCT) are imaging methods that quantify bone mass and structural aspects of bone quality. They do not measure turnover or mineralization. Therefore, they cannot be used alone to determine ROD type or assess completely disease severity. Furthermore, monitoring disease activity with imaging methods may be difficult because there are no data correlating changes in the parameters measured by these tools with changes in fracture risk.
DXA is widely available and is the clinical standard for measuring fracture risk in patients with healthy kidney function. However, fracture risk screening by DXA in CKD has been controversial. DXA does not have sufficient resolution to discriminate between cortical and trabecular bone, it provides a composite measure of cortical and trabecular compartments, and is unable to determine turnover or mineralization. Furthermore, as a result of study limitations, the results of cross-sectional and prospective studies on fracture discrimination and prediction were inconsistent [20,24- . Indeed, these prospective trials have begun to clarify and validate the use of DXA in CKD and help clinicians use and interpret DXA imaging. They indicate that in CKD, fracture risk screening is possible by imaging the forearm, total hip or femoral neck and that the World Health Organization definition of osteoporosis (T-score 2.5) is clinically relevant. High-resolution imaging methods measure and quantify cortical and trabecular three-dimensional (volumetric) BMD, geometry, microarchitecture, and strength. Currently, these tools are used for research. QCT has a resolution of 300 mm 3 and measures volumetric BMD and the geometry of cortical and trabecular compartments. Peripheral QCT has been used to assess the skeletal effects of CKD in patients predialysis, on hemodialysis, and after kidney transplantation. Studies reported that in CKD patients, cortical deficits predominated [28, 37] and cortical abnormalities both discriminated [28] and predicted fracture [38] . Similarly, HR-pQCT separately measures cortical and trabecular volumetric BMD and geometry, but its higher nominal resolution of 82 mm 3 permits quantification of trabecular number, thickness, and separation. Finite element analysis, a computational method to quantify bone strength, can be applied to three-dimensional HR-pQCT datasets to measure strength either of whole bone or of individual cortical and trabecular compartments. Recently, advanced HR-pQCT processing methods have been developed to characterize cortical porosity [39, 40] and trabecular plate and rod structure [41] . In patients from across the CKD spectrum, our group and others have demonstrated in cross-sectional and prospective studies that measurement of bone mass, geometry, and microarchitecture by HR-pQCT at the distal radius and tibia discriminated fracture status [24, 25, [42] [43] [44] , detected abnormalities in bone quality that negatively impact bone strength [45] [46] [47] , and elucidated underlying microstructural defects that result in BMD abnormalities measured by DXA [45, 46] . For example, in a prospective study of 54 patients with moderate-to-end-stage renal disease, we found that mean annualized losses of areal BMD at the forearm were 2.9% [45] . With HR-pQCT, we identified microstructural mechanisms of forearm bone loss detected by DXA; there was significant loss of cortical area (-2.9%), density (-1.3%), and thickness (-2.8%) and significant increases in cortical porosity (þ4.2%). Prospective studies are needed to determine whether the measurement of bone mass and microarchitecture by HR-pQCT predicts fracture, and whether therapies that mitigate microarchitectural abnormalities detected by HR-pQCT protect against fracture.
The value of combining measures of areal BMD by DXA with measures of bone geometry and microarchitecture by HR-pQCT to enhance fracture prediction above that of either imaging test alone is not established. In a cross-sectional study of CKD patients with and without fracture, Jamal et al. [26] studied the value of combing measures from DXA with measures from HR-pQCT. Areal BMD was measured by DXA at the mainly trabecular ultradistal radius, and total volumetric BMD and cortical thickness were measured by HR-pQCT at the distal radius. When HR-pQCT measures were added to areal BMD by DXA, the area under the curve (AUC) was 0.81 [95% confidence interval (CI) 0.74-0.88]. This was not significantly different from the areal BMD obtained by DXA at the radius alone (AUC 0.80; 95% CI 0.74-0.87; P ¼ 0.4). The reasons for this negative finding are likely owing to redundancies in parameters measured by these imaging methods. Both DXA and HR-pQCT measure structural aspects of bone quality. Thus, an enhancement of assessing bone disease severity in CKD-MBD will most likely be obtained by combining structural with dynamic measures of bone quality.
ASSESSING BONE TURNOVER AND OSTEOMALACIA
There are no recent bone biopsy studies that update the historical literature on assessing turnover and osteomalacia noninvasively. Nonetheless, their evaluation is an essential component of assessing bone disease. Turnover may range from extremely low (adynamic bone disease) to extremely high (osteitis fibrosa cystica), turnover may change over time, and turnover-type affects treatment. Pharmacologic agents that protect against fracture alter remodeling rates. Although antiresorptive agents may be used in patients with high turnover, they are contraindicated in patients with adynamic bone disease. Similarly, although osteoanabolic agents (i.e., Teriparatide) may be used in patients with low turnover, they are contraindicated in patients with high turnover. As discussed, bone biopsy is not always possible or practical. Thus, a noninvasive approach to turnover assessment is desirable. Despite assay limitations, noninvasive assessment can be achieved with reasonable accuracy by measuring circulating levels of parathyroid hormone (PTH) and bone turnover markers (BTMs) [48] [49] [50] [51] [52] [53] . Bone formation markers, such as bonespecific alkaline phosphatase (BSAP), osteocalcin, and procollagen type-1 N-terminal propeptide (P1NP), are markers of osteoblast function. Bone resorption markers, such as tartrate-resistant acid phosphatase 5b (Trap-5b) and C-terminal telopeptides of type I collagen (CTX) are markers of osteoclast number and function, respectively. In clinical practice, PTH and BSAP are the most commonly used markers of turnover in CKD-MBD. In general, extremes of PTH predict extremes of bone turnover both in predialysis [52] and dialysis-dependent [53] patients. Unfortunately, the prediction of the underlying histology is less discriminatory when PTH levels are within the middle range. For BTMs, reference ranges in CKD populations do not exist and some BTMs are renally cleared (osteocalcin, P1NP monomer and CTX). Thus, their use and interpretation in CKD-MBD is challenging. In general, their predictive values are improved at the extremes of BTM levels, and with combining multiple BTMs with or without PTH [48] [49] [50] . Low vitamin D levels, and low levels of PTH in conjunction with high levels of BSAP, have been correlated with osteomalacia, and osteomalacia has been associated with hip fractures. The measurement of PTH and BTMs may be more helpful in predicting bone loss and fractures than in predicting type of turnover per se [24,33 & , 45,46,54] . In a cross-sectional study of predialysis CKD patients with and without fracture, we reported that higher levels of PTH and BTMs were associated with lower cortical and trabecular density, and with thinner cortices and trabeculae [24] . Moreover, higher levels of P1NP, osteocalcin, CTX, and Trap-5b discriminated fracture [24] . In prospective studies of CKD patients both before [45] and after kidney transplantation [46] , our group evaluated the effects of remodeling measured by circulating levels of PTH and BTMs on changes in bone mass, geometry, microarchitecture, and strength measured by HR-pQCT. Higher concentrations of PTH, BSAP, osteocalcin, P1NP, Trap-5b, and CTX predicted loss of cortical area, density, and thickness, increases in cortical porosity, and decreases in bone strength. Regarding the ability of PTH and BTMs to predict fracture, a prospective study of ESRD patients reported that fracture risk was higher in patients with either low (<150 pg/ml) or high (>300 pg/ml) PTH levels, and with higher BSAP levels [33 & ]. In kidney transplant recipients, PTH levels 130 pg/ml or higher at 3-month posttransplantation predicted incident fractures [54] . These data indicate that higher remodeling rates, as assessed by PTH and clinically available BTMs, result in bone loss, deterioration of cortical and trabecular microarchitecture, and predict fracture. Prospective fracture studies of PTH and BTMs that include all CKD stages and demographic groups are needed to validate these findings, provide reference ranges that correlate with bone histology, and correlate changes in PTH and BTMs with changes in fracture risk.
CAN WE NONINVASIVELY ASSESS BONE DISEASE IN CHRONIC KIDNEY DISEASE?
Noninvasive assessment of bone disease needs to detect abnormalities in bone structure, remodeling, and mineralization, predict clinical outcomes, inform treatment decisions, and predict changes in clinical outcomes in response to treatment. We have developed a prototype approach to stratify patients into those who do and do not require bone biopsy. Although this approach requires validation in prospective fracture trials and against bone histology, our group explored a modified version [24] . In a cross sectional study of CKD patients with and without fracture, we investigated whether a non-invasive approach that incorporated the assessment of bone structure and remodeling could assess the severity of bone disease and improve the classification of fracture status. This cross-sectional study included 82 patients with stage 3-5 CKD (23 with and 59 without fractures); we reported that higher levels of PTH and BTMs were associated with more severely deteriorated microarchitecture and that fracture discrimination was significantly improved by combining markers of formation (P1NP, osteocalcin) and resorption (Trap-5b) with areal BMD at the femoral neck. Longitudinal studies are needed to determine whether combining measures of bone imaging and turnover predict fracture, inform clinical decision making, and improve clinical outcomes. In addition, non-invasive tools to assess the severity of bone disease cannot be confidently used to decide upon treatment until we have non-invasive measures of osteomalacia, BTMs that more accurately reflect bone remodeling, reference ranges for BTMs that correlate with histology across the CKD spectrum, and an understanding of the relationships between changes in BTMs and changes in bone histology and fracture risk. Furthermore, changes in bone mass and microarchitecture over time have not been correlated with changes in either disease severity or fracture risk, and the optimal time-interval for disease monitoring has not been established. Thus, the decision to treat and to monitor treatment response in a CKD patient managed with vitamin D analogs, or an antiresorptive or osteoanabolic agent, may not be completely possible without a bone biopsy.
CONCLUSION
Bone disease is common in CKD and its clinical outcomes are potentially life-threatening. The current gold standard to assess ROD is invasive and suboptimal for disease screening and management. Advances in imaging methods enable the noninvasive measurement of structural aspects of bone disease that drive increased skeletal fragility; however, before the ''virtual bone biopsy'' is ready for prime time, more accurate methods of noninvasively assessing turnover and osteomalacia, validated against bone histology, are needed. Finally, prospective fracture trials are necessary to demonstrate that clinical bone outcomes are improved by a noninvasive approach to ROD management.
